Medpace demonstrates strong financial performance and growth in the CRO market, despite facing challenges in the short term.

Faced with the encroaching threats of patent expirations and generics, biopharma companies in 2024 invested 33% more in ...

Halozyme Therapeutics (NASDAQ:HALO – Get Free Report)‘s stock had its “buy” rating restated by equities research analysts at ...

IRA has unintended consequences on investment landscape for small- and large-molecule drugs stifling the development of new ...

Over two-thirds of the top 20 global firms reported a decline in market capitalisation. The biopharmaceutical industry showed ...

CAMBRIDGE, MA – Seres Therapeutics, Inc. (NASDAQ:MCRB), a biopharmaceutical company specializing in pharmaceutical preparations, announced on Monday the appointment of Dr. Hans-Juergen Woerle as a new ...

Regeneron Pharmaceuticals (NASDAQ:REGN – Get Free Report) had its target price decreased by equities research analysts at Leerink Partners from $980.00 to $862.00 in a research note issued on Tuesday.

About Y-mAbs Y-mAbs is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, radioimmunotherapy and antibody-based therapeutic cancer products. The ...

Monoclonal antibodies, or mAbs, are important tools in medicine. These laboratory-made proteins are widely used in treatments ...

Wong, Founder and CEO of HCW Biologics, commented, “The FDA’s clearance to initiate our first-in-human clinical trial for HCW9302 brings us one step closer to advancing a potentially transformative ...